Olivier Pasquier Joins CYTOO as Chief Commercial Officer
News Mar 18, 2013
Former Senior Marketing Manager Europe at QIAGEN, with more than 10 years experience in biology and biotechnology, he is passionate about biotech breakthroughs. He joins the team to lead the commercial success of CYTOO's 2D+ Cell Culture Platform and develop new markets in cell based assays and screening.
François Chatelain, CEO of CYTOO, says “We're delighted to welcome Olivier at CYTOO: I have no doubt that his insights, energy and business initiatives will be really impactful on CYTOO’s development!"
“It is an honour for me to join the executive team of CYTOO”, says Olivier Pasquier. “This company has a unique talented team, a breakthrough technology, a secured financial background, able to deeply change the game in the cell-based assay science. I want to make sure that every lab using cell culture in the world accesses micropatterns and scientific expertise available at CYTOO.”
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE
From Human Biopsy to Complex Gut Physiology on a ChipNews
Organ Chip technology using donor-derived human intestinal cells offers advantages over organoids and creates new opportunities for personalized medicine.READ MORE
Liver-on-a-chip Used to Test Hepatitis B Virus InfectionNews
Scientists at Imperial College London have become the first in the world to test how pathogens interact with artificial human organs.READ MORE